IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: COLEMAN et al.

Application Number: 08/972,301

Filed: November 18, 1997

Title: Endothelial-Monocyte

Activating Polypeptide III



Group Art Unit: 1646

Examiner: E. Kemmerer

Attny. Docket No.: PF206D1

FEE TRANSMITTAL SHEET

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$642.00.

The claim amendment fee has been estimated as shown below:

	(Col. 1)		(Col. 2)	(C	Col. 3)		1ALL TITY			ER THAN A LL ENTITY	
Claims Remaining After Amendment			Highest No. Previously Paid For	Present Extra		Rate	Add. Fee	or	Rate	Add. Fee	
Total	47	Minus	20	=	27	X9	\$ **		X18	\$ 4	186.00
Indep	5	Minus	3	=	2	X39	\$ **		X78	\$	156.00
First Presentation of Multiple Dep. Claims					+ 130		\$** + 260			\$ **	
					Total		\$ **	or	Total	\$ 6	42.00

Please charge the required fee, and any other fee deemed necessary, to Deposit Account No. 08-3425. A duplicate of this sheet is enclosed.

Respectfully submitted,

Dated: July 6, 2000

Joseph J. Kenny

Reg. No. 43,710)

Agent for Applicants

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, MD 20850 Telephone: (301) 610-5800

Enclosure

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: COLEMAN, et a

Application Number: 08/972,301

Filed: November 18, 1997

Title: ENDOTHELIAL MONOCYTE

ACTIVATING POLYPEPTIDE III

Group Art Unit: 1646

Examiner: E. Kemmerer

Attny. Docket No. PF206D1

20/E 1.9.) 1/1.3/a)

RESPONSE AND AMENDMENT UNDER 37 C.F.R. § 1.111

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Official Action dated January 7, 2000 (Paper No. 16), Applicants respectfully request that the Examiner enter the following amendments. Applicants submit concurrently herewith: (a) a Fee Transmittal Sheet; (b) a Petition for an Extension of Time for a period of time of three months up to and including July 7, 2000; and (c) an Associate Power of Attorney. Please amend the application as follows.

In the Specification:

Please amend the specification as follows:

At page 33, line 23, please delete "Example 5" and replace therefor -- Example 4--.

In the claims:

Please amend the claims as follows:

Please cancel claims 57-61, 71, 74, 77-89 without prejudice.

Please add the following new claims:

--90. (New) An isolated protein comprising amino acid residues 1 to 168 of SEQ

ID NO:2.

07/07/2000 EMAXHEND 00000018 083425 06972301